AbbVie invests $195 million in the future of medicine!

AbbVie invests $195 million in the future of medicine!

AbbVie, the US pharmaceutical company, has underpinned its growth strategy with an impressive announcement to expand its production site in North Chicago. On August 13, 2025, the company announced that it was planning a $195 million expansion to increase drug manufacturing in neuroscience, immunology and oncology. This measure is part of an ambitious program that AbbVie wants to implement in the USA over the next ten years with a total amount of 10 billion dollars. Construction is scheduled to start in autumn 2025, while commissioning is scheduled for 2027.

The positive developments at AbbVie come as the company reported impressive second-quarter results. Sales rose 6.6 percent to $15.4 billion, beating analysts' expectations of just $15.0 billion. Adjusted earnings per share were $2.97, beating estimates of $2.91. These results are based largely on the growth of new products and AbbVie's strong market position.

Growth through innovation

Sales of AbbVie's newer products are particularly noteworthy: the psoriasis drug Skyrizi recorded an increase of 62.2 percent to $4.42 billion, while the rheumatism drug Rinvoq increased by 41.8 percent to $2.03 billion. This clear focus on innovative medicines has helped the company overcome challenges related to patent protection for Humira, whose revenue fell 58 percent to $1.18 billion compared to last year. Before the patent expiration date, Humira had brought AbbVie over $21 billion in 2022.

In addition, AbbVie is raising its earnings forecast for the current year, with adjusted earnings per share now expected to be between $11.88 and $12.08, compared to the previous range of $11.67 to $11.87. These positive prospects were well received by investors: AbbVie shares responded with an increase of over five percent and have increased by almost 15 percent since the beginning of the year. Piper Sandler gives the stock an “Overweight” rating and a price target of $231.

Sustainable income and dividends

AbbVie stock remains attractive not only due to the growth of its core revenue streams, but also because of its stable dividend yield of 3.4 percent. Analysts also recommend an increase in M&A activity in the medium to long-term strategic outlook. Also impressive is that AbbVie has no major patent expirations until the end of the decade, with the exception of Vraylar, whose patent protection expires by 2030 and represents about 6 percent of its expected global revenues in 2025.

Overall, AbbVie is a strong company with solid fundamentals and a clear growth strategy that continues to be promising for investors. Both the recent figures and the planned expansion demonstrate the company's commitment to researching and developing new therapeutic approaches that will enrich the portfolio in the coming years.

For more information and details, please visit the full reports on boerse-express.com and deraktionaer.de.